Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Experimental therapeutics for patients with myeloproliferative neoplasias.

Cancer - 15 Feb 2011

Agrawal Meetu, Garg Ravin J, Cortes Jorge, Kantarjian Hagop, Verstovsek Srdan, Quintas-Cardama Alfonso

Abstract excerpt

Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) are characterized by stem cell-derived, unrestrained clonal myeloproliferation. The World Health Organization classification system, proposed in 2008, identifies 7 distinct categories of Ph-negative MPNs including essential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Delivery Systems
Share to Histone Deacetylase Inhibitors
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Polyethylene Glycols

Share to Thalidomide

Source

Identifiers

PMID: 20922795
DOI: 10.1002/cncr.25672

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20922795-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Experimental therapeutics for patients with myeloproliferative neoplasias.PMID 20922795Read ↗

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Semantic proximity Read ↗

Experimental therapy in myelofibrosis with myeloid metaplasia.Semantic proximity Read ↗

Targets in MPNs and potential therapeutics.Semantic proximity Read ↗

Philadelphia Chromosome–Negative Myeloproliferative Disorders: Biology and TreatmentSemantic proximity Read ↗

Current treatment concepts of Philadelphia-negative MPN.Semantic proximity Read ↗

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

Jak-2 positive myeloproliferative neoplasms.Semantic proximity Read ↗

Kinase drug discovery approaches in chronic myeloproliferative disorders.Semantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

JAK2 kinase inhibitors and myeloproliferative disordersSemantic proximity Read ↗

Oncogenes in myeloproliferative disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.